[{"id":"c04546a7-eee3-4054-89be-d7ee08a9cd8a","acronym":"OpcemISA","url":"https://clinicaltrials.gov/study/NCT03669718","created_at":"2021-01-18T18:00:19.264Z","updated_at":"2024-07-02T16:35:24.902Z","phase":"Phase 2","brief_title":"A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC","source_id_and_acronym":"NCT03669718 - OpcemISA","lead_sponsor":"ISA Pharmaceuticals","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • ISA101b"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 194","initiation":"Initiation: 11/30/2018","start_date":" 11/30/2018","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-12-29"}]